View in EDS HTML Full Text PDF Full Text

Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.

Saved in:
Bibliographic Details
Title: Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.
Authors: Li H; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Yuan L; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Liu P; Yichuan Community Health Service Center of Putuo District, Shanghai, China., Liu Y; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China., Huang D; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China., Ding H; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China., Jin W; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Liu J; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Wang H; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China., Song L; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China.
Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2025 Sep 15; Vol. 16, pp. 1657481. Date of Electronic Publication: 2025 Sep 15 (Print Publication: 2025).
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41030855
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+H%22">Li H</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yuan+L%22">Yuan L</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Liu+P%22">Liu P</searchLink>; Yichuan Community Health Service Center of Putuo District, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Huang+D%22">Huang D</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Ding+H%22">Ding H</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Jin+W%22">Jin W</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Liu+J%22">Liu J</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Song+L%22">Song L</searchLink>; Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.; Department of Endocrinology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.; Institute of Osteoporosis and Metabolic Bone Diseases, School of Medicine, Tongji University, Shanghai, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101555782%22">Frontiers in endocrinology</searchLink> [Front Endocrinol (Lausanne)] 2025 Sep 15; Vol. 16, pp. 1657481. <i>Date of Electronic Publication: </i>2025 Sep 15 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101555782 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1664-2392 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216642392%22">16642392 </searchLink><i>NLM ISO Abbreviation: </i>Front Endocrinol (Lausanne) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41030855
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fendo.2025.1657481
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1657481
    Titles:
      – TitleFull: Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li H
      – PersonEntity:
          Name:
            NameFull: Yuan L
      – PersonEntity:
          Name:
            NameFull: Liu P
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Huang D
      – PersonEntity:
          Name:
            NameFull: Ding H
      – PersonEntity:
          Name:
            NameFull: Jin W
      – PersonEntity:
          Name:
            NameFull: Liu J
      – PersonEntity:
          Name:
            NameFull: Wang H
      – PersonEntity:
          Name:
            NameFull: Song L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 09
              Text: 2025 Sep 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 1664-2392
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in endocrinology
              Type: main
ResultId 1